Development of New Drugs from the Iminosugar Class

References

1. Horne G. Wilson F.X. Tinsley J. Williams D.H. Storer R. Iminosugars past, present and future: Medicines for tomorrow. Drug Discov. Today 2011 16 3-4 107 118 10.1016/j.drudis.2010.08.017 20817006
   [Google Scholar]
2. Asano N. Naturally occurring iminosugars and related compounds: Structure, distribution, and biological activity. Curr. Top. Med. Chem. 2003 3 5 471 484 10.2174/1568026033452438 12570862
   [Google Scholar]
3. Martin O.R. Compain P. Iminosugars: From Synthesis to Therapeutic Applications. Chichester, West Sussex, England Hoboken, NJ, John Wiley and Sons 2007 10.1002/9780470517437
   [Google Scholar]
4. Mellor H.R. Neville D.C.A. Harvey D.J. Platt F.M. Dwek R.A. Butters T.D. Cellular effects of deoxynojirimycin analogues: Inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides. Biochem. J. 2004 381 3 867 875 10.1042/BJ20031824 15128289
   [Google Scholar]
5. Esposito A. D’Alonzo D. De Fenza M. De Gregorio E. Tamanini A. Lippi G. Dechecchi M.C. Guaragna A. Synthesis and therapeutic applications of iminosugars in cystic fibrosis. Int. J. Mol. Sci. 2020 21 9 3353 10.3390/ijms21093353 32397443
   [Google Scholar]
6. Fan J.Q. Ishii S. Asano N. Suzuki Y. Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 1999 5 1 112 115 10.1038/4801 9883849
   [Google Scholar]
7. Parida I.S. Takasu S. Nakagawa K. A comprehensive review on the production, pharmacokinetics and health benefits of mulberry leaf iminosugars: Main focus on 1-deoxynojirimycin, d-fagomine, and 2-O-ɑ-d-galactopyra-] nosyl-DNJ. Crit. Rev. Food Sci. Nutr. 2023 63 19 3468 3496 10.1080/10408398.2021.1989660 34658276
   [Google Scholar]
8. Liu Q. Liu Y. Liu T. Fan J. Xia Z. Zhou Y. Deng X. Expanding horizons of iminosugars as broad-spectrum anti-virals: Mechanism, efficacy and novel developments. Nat. Prod. Bioprospect. 2024 14 1 55 10.1007/s13659‑024‑00477‑5 39325109
   [Google Scholar]
9. García Fernández J.M. Ortiz Mellet C. Novel therapies for orphan diseases. ACS Med. Chem. Lett. 2019 10 7 1020 1023 10.1021/acsmedchemlett.9b00242 31312401
   [Google Scholar]
10. Alonzi D.S. Scott K.A. Dwek R.A. Zitzmann N. Iminosugar antivirals: The therapeutic sweet spot. Biochem. Soc. Trans. 2017 45 2 571 582 10.1042/BST20160182 28408497
    [Google Scholar]
11. Simone M.I. Wood A. Campkin D. Kiefel M.J. Houston T.A. Recent results from non-basic glycosidase inhibitors: How structural diversity can inform general strategies for improving inhibition potency. Eur. J. Med. Chem. 2022 235 114282 10.1016/j.ejmech.2022.114282 35367706
    [Google Scholar]
12. Ferjancic Z. Bihelovic F. Vulovic B. Matovic R. Trmcic M. Jankovic A. Pavlovic M. Djurkovic F. Prodanovic R. Djurdjevic Djelmas A. Kalicanin N. Zlatovic M. Sladic D. Vallet T. Vignuzzi M. Saicic R.N. Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies. J. Enzyme Inhib. Med. Chem. 2024 39 1 2289007 10.1080/14756366.2023.2289007 38086763
    [Google Scholar]
13. Thaler M. Ofman T.P. Kok K. Heming J.J.A. Moran E. Pickles I. Leijs A.A. van den Nieuwendijk A.M.C.H. van den Berg R.J.B.H.N. Ruijgrok G. Armstrong Z. Salgado-Benvindo C. Ninaber D.K. Snijder E.J. van Boeckel C.A.A. Artola M. Davies G.J. Overkleeft H.S. van Hemert M.J. Epi -Cyclophellitol cyclosulfate, a mechanism-based endoplasmic reticulum α-glucosidase II inhibitor, blocks replication of SARS-COV-2 and other coronaviruses. ACS Cent. Sci. 2024 10 8 1594 1608 10.1021/acscentsci.4c00506 39220688
    [Google Scholar]
14. Rezvani K. Shpall E. Basar R. Natural killer cell immunotherapy for the treatment or prevention of SARS-CoV-2 infection. WO Patent 2021232050A1, 2021
    [Google Scholar]
15. Marcuccio S. M. Morton D. A. V. Tucker S. P. Glucosidase inhibitors for the treatment and prevention of pulmonary infections. WO Patent 2022040741A1, 2021
    [Google Scholar]
16. Kuchipudi S. Use of iminosugars as prophylactic and therapy against COVID-19 / SARS-CoV-2. US Patent 11141419B1, 2021
    [Google Scholar]
17. Suresh K. Use of migalastat for treating fabry disease in pregnant patients. US Patent 11357784B2 2019
    [Google Scholar]
18. Suzuki Y. Chaperone therapy: Stabilization and enhancement of endogenous and exogenous lysosomal enzymes. Brain Dev. 2025 47 1 104298 10.1016/j.braindev.2024.10.006 39549634
    [Google Scholar]
19. Kerkovich D. Combination product containing trehalose and miglustat for treating lysosomal diseases. EP patent 3944858A1 2020
    [Google Scholar]
20. Chafer-Dolz B. Cecilia J.M. Imbernón B. Núñez-Delicado E. Casaa-Giner V. Cerón-Carrasco J.P. Insecticide discovery by drug repurposing: New synergistic inhibitors against Periplaneta americana. New J. Chem. 2023 47 37 17234 17243 10.1039/D3NJ02676K
    [Google Scholar]
21. Haider A.J. Al-Kinani M.A. Al-Musawi S. Preparation and characterization of gold coated super paramagnetic iron nanoparticle using pulsed laser ablation in liquid method. Key Eng. Mater. 2021 886 77 85 10.4028/www.scientific.net/KEM.886.77
    [Google Scholar]